Gene therapy of endometriosis introduced by polymeric micelles with glycolipid-like structure

Biomaterials

Volumn 33, Issue 2, 2012, Pages 634-643

  Zhao, Meng Dan ^a   Sun, Yan Mei ^a   Fu, Guo Fang ^a   Du, Yong Zhong ^b   Chen, Feng Ying ^a   Yuan, Hong ^b   Zheng, Cai Hong ^a   Zhang, Xin Mei ^a   Hu, Fu Qiang ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Endometriosis; Gene therapy; Glycolipid like; PEDF; Polymeric micelles

Indexed keywords

APOPTOTIC; CLINICAL TREATMENTS; ENDOMETRIOSIS; GENE DELIVERY SYSTEMS; GLYCOLIPID-LIKE; HYDRODYNAMIC DIAMETER; INTRAVENOUS INJECTIONS; MICROVESSEL DENSITY; NARROW SIZE DISTRIBUTIONS; PEDF; POLYMERIC MICELLE; POLYMERIC MICELLES; RAT MODEL; REPRODUCTIVE ORGANS; SIDE EFFECT; SMOOTH MUSCLES; VON WILLEBRAND FACTOR;

CHEMOTHERAPY; GENE TRANSFER; MICELLES; NANOPARTICLES; POLYMERS;

GENE THERAPY;

ALPHA SMOOTH MUSCLE ACTIN; CHITOSAN; DANAZOL; NANOPARTICLE; PIGMENT EPITHELIUM DERIVED FACTOR; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPE; ENDOMETRIOSIS; ENDOMETRIUM ATROPHY; FEMALE; GENE THERAPY; HYDRODYNAMICS; MICELLE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; APOPTOSIS; CHITOSAN; DISEASE MODELS, ANIMAL; DNA; ENDOMETRIOSIS; EYE PROTEINS; FEASIBILITY STUDIES; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GLYCOLIPIDS; MICELLES; MICROSCOPY, ELECTRON, TRANSMISSION; NERVE GROWTH FACTORS; PARTICLE SIZE; PLASMIDS; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SERPINS;

RATTUS;

EID: 80055107930     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.09.077     Document Type: Article

References (56)

1. Lebovic D.I., Mueller M.D., Taylor R.N. Immunobiology of endometriosis. Fertil Steril 2001, 75:1-10.
2. Nothnick W.B. Endometriosis: in search of optimal treatment. Minerva Ginecol 2010, 62:17-31.
3. Verma I.M., Somia N. Gene therapy-promises, problems and prospects. Nature 1997, 389:239-242.
4. Han S., Mahato R.I., Sung Y.K., Kim S.W. Development of biomaterials for gene therapy. Mol Ther 2000, 2:302-317.
5. Forrest M.L., Koerber J.T., Pack D.W. A degradable polyethyleneimine derivative with low toxicity for highly efficient gene delivery. Bioconjug Chem 2003, 14:934-940.
6. Kong H.J., Liu J., Riddle K., Matsumoto T., Leach K., Mooney D.J. Non-viral gene delivery regulated by stiffness of cell adhesion substrates. Nat Mater 2005, 4:460-464.
7. Neu M., Fischer D., Kissel T. Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives. J Gene Med 2005, 7:992-1009.
8. Feng H., Dong C.M. Preparation, characterization, and self-assembled properties of biodegradable chitosan-poly(L-lactide) hybrid amphiphiles. Biomacromolecules 2006, 7:3069-3075.
9. Dass C.R., Contreras K.G., Dunstan D.E., Choong P.F. Chitosan microparticles encapsulating PEDF plasmid demonstrate efficacy in an orthotopic metastatic model of osteosarcoma. Biomaterials 2007, 28:3026-3033.
10. Borchard G. Chitosans for gene delivery. Adv Drug Deliv Rev 2001, 52:145-150.
11. Mansouri S., Lavigne P., Corsi K., Benderdour M., Beaumont E., Fernandes J.C. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur J Pharm Biopharm 2004, 57:1-8.
12. Hu F.Q., Zhao M.D., Yuan H., You J., Du Y.Z., Zeng S. A novel chitosan oligosaccharide-stearic acid micelles for gene delivery: properties and in vitro transfection studies. Int J Pharm 2006, 315:158-166.
13. Ozbas-Turan S., Aral C., Kabasakal L., Keyer-Uysal M., Akbuga J. Co-encapsulation of two plasmids in chitosan microspheres as a non-viral gene delivery vehicle. J Pharm Pharm Sci 2003, 6:27-32.
14. Felgner J.H., Kumar R., Sridhar C.N., Wheeler C.J., Tsai Y.J., Border R., et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 1994, 269:2550-2561.
15. Miglietta A., Cavalli R., Bocca C., Gabriel L., Gasco M.R. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm 2000, 210:61-67.
16. Foged C., Nielsen H.M., Frokjaer S. Liposomes for phospholipase A2 triggered siRNA release: preparation and in vitro test. Int J Pharm 2007, 331:160-166.
17. Clements B.A., Incani V., Kucharski C., Lavasanifar A., Ritchie B., Uludaĝ H. A comparative evaluation of poly-L-lysine-palmitic acid and lipofectamine 2000 for plasmid delivery to bone marrow stromal cells. Biomaterials 2007, 28:4693-4704.
18. Lu Z.Z., Wu J., Sun T.M., Ji J., Yan L.F., Wang J. Biodegradable polycation and plasmid DNA multilayer film for prolonged gene delivery to mouse osteoblasts. Biomaterials 2008, 29:733-741.
19. May K., Becker C.M. Endometriosis and angiogenesis. Minerva Ginecol 2008, 60:245-254.
20. Becker C.M., D'Amato R.J. Angiogenesis and antiangiogenic therapy in endometriosis. Microvasc Res 2007, 74:121-130.
21. Becker C.M., Sampson D.A., Rupnick M.A., Rohan R.M., Efstathiou J.A., Short S.M., et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 2005, 84:1144-1155.
22. Machado D.E., Berardo P.T., Landgraf R.G., Fernandes P.D., Palmero C., Alves L.M., et al. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis with an antiangiogenic effect in a rat model. Fertil Steril 2010, 93:2674-2679.
23. Dawson D.W., Volpert O.V., Gillis P., Crawford S.E., Xu H., Benedict W., et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999, 285:245-248.
24. Vernon M.W., Wilson E.A. Studies on the surgical induction of endometriosis in the rat. Fertil Steril 1985, 44:684-694.
25. Hu F.Q., Ren G.F., Yuan H., Du Y.Z., Zeng S. Shell cross-linked stearic acid grafted chitosan oligosaccharide self-aggregated micelles for controlled release of paclitaxel. Colloids Surf B Biointerfaces 2006, 50:97-103.
26. Zhao M.D., Hu F.Q., Du Y.Z., Yuan H., Chen F.Y., Lou Y.M., et al. Coadministration of glycolipid-like micelles loading cytotoxic drug with different action site for efficient cancer chemotherapy. Nanotechnology 2009, 20:055102.
27. Hu F.Q., Wu X.L., Du Y.Z., You J., Yuan H. Cellular uptake and cytotoxicity of shell crosslinked stearic acid-grafted chitosan oligosaccharide micelles encapsulating doxorubicin. Eur J Pharm Biopharm 2008, 69:117-125.
28. Nap A.W., Griffi{ligature}oen A.W., Dunselman G.A., Bouma-Ter Steege J.C., Thijssen V.L., Evers J.L., et al. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab 2004, 89:1089-1095.
29. Meresman G.F., Vighi S., Buquet R.A., Contreras-Ortiz O., Tesone M., Rumi L.S. Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis. Fertil Steril 2000, 74:760-766.
30. Olivares C., Ricci A., Bilotas M., Barañao R.I., Meresman G. The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. Fertil Steril 2011, 96:428-433.
31. Kunath K., von Harpe A., Fischer D., Petersen H., Bickel U., Voiqt K., et al. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. J Control Release 2003, 89:113-125.
32. Katayose S., Kataoka K. Remarkable increase in nuclease resistance of plasmid DNA through supramolecular assembly with poly(ethylene glycol)-Poly(L-lysine) block copolymer. J Pharm Sci 1998, 87:160-163.
33. Mislick K.A., Baldeschwieler J.D. Evidence for the role of proteoglycans in cation- mediated gene transfer. Proc Natl Acad Sci U S A 1996, 93:12349-12354.
34. Ting C.L., Wang Z.G. Interactions of a charged nanoparticle with a lipid membrane: implications for gene delivery. Biophys J 2011, 100:1288-1297.
35. Nonaka K., Kazama S., Goto A., Fukuda H., Yoshioka H., Yoshioka H. Spin probe study on the interaction of chitosan-derived polymer surfactants with lipid membrane. J Colloid Interface Sci 2002, 246:288-295.
36. Fang N., Chan V. Chitosan-induced restructuration of mica-supported phospholipid bilayer: an atomic force microscopy study. Biomacromolecules 2003, 49:1596-1604.
37. Ruponen M., Honkakoski P., Rönkkö S., Pelkonen J., Tammi M., Urtti A. Extracellular and intracellular barriers in non-viral gene delivery. J Control Release 2003, 93:213-217.
38. Liu W.G., Zhang X., Sun S.J., Sun G.J., Yao K.D., Liang D.C., et al. N-alkylated chitosan as a potential nonviral vector for gene transfection. Bioconjug Chem 2003, 14:782-789.
39. Sugiyama M., Matsuura M., Takeuchi Y., Kosaka J., Nango M., Oku N. Possible mechanism of polycation liposome (PCL)-mediated gene transfer. Biochim Biophys Acta 2004, 1660:24-30.
40. Masuda T., Akita H., Nishio T., Niikura K., Kogure K., Ijiro K., et al. Development of lipid particles targeted via sugar-lipid conjugates as novel nuclear gene delivery system. Biomaterials 2008, 29:709-723.
41. Haribalaganesh R., Sheikpranbabu S., Banumathi E., Gurunathan S. Pigment epithelium-derived factor inhibits erythropoietin-induced retinal endothelial cell angiogenesis by suppression of PI3K/Akt pathway. Exp Eye Res 2010, 90:726-733.
42. Yang J., Chen S., Huang X., Han J., Wang Q., Shi D., et al. Growth suppression of cervical carcinoma by pigment epithelium-derived factor via anti-angiogenesis. Cancer Biol Ther 2010, 9:967-974.
43. Wang H., Gorpudolo N., Li Y., Feng D., Wang Z., Zhang Y. Elevated vascular endothelia growth factor-A in the serum and peritoneal fluid of patients with endometriosis. J Huazhong Univ Sci Technolog Med Sci 2009, 29:637-641.
44. Machado D.E., Berardo P.T., Palmero C.Y., Nasciutti L.E. Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases. J Exp Clin Cancer Res 2010, 29:4.
45. Bourlev V., Volkov N., Pavlovitch S., Lets N., Larsson A., Olovsson M. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction 2006, 132:501-509.
46. Garcia M., Fernandez-Garcia N.I., Rivas V., Carretero M., Escamez M.J., Gonzalez-Martin A., et al. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res 2004, 64:5632-5642.
47. Abe R., Shimizu T., Yamagishi S., Shibaki A., Amano S., Inagaki Y., et al. Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol 2004, 164:1225-1232.
48. Yang H., Cheng R., Liu G., Zhong Q., Li C., Cai W., et al. PEDF inhibits growth of retinoblastoma by anti-angiogenic activity. Cancer Sci 2009, 100:2419-2425.
49. Cheung L.W., Au S.C., Cheung A.N., Ngan H.Y., Tombran-Tink J., Auersperg N., et al. Pigment epithelium-derived factor is estrogen sensitive and inhibits the growth of human ovarian cancer and ovarian surface epithelial cells. Endocrinology 2006, 147:4179-4191.
50. Gao G., Ma J. Tipping the balance for angiogenic disorders. Drug Discov Today 2002, 7:171-172.
51. Ren J.G., Jie C., Talbot C. How PEDF prevents angiogenesis: a hypothesized pathway. Med Hypotheses 2005, 64:74-78.
52. Elayappan B., Ravinarayannan H., Pasha S.P., Lee K.J., Gurunathan S. PEDF inhibits VEGF- and EPO- induced angiogenesis in retinal endothelial cells through interruption of PI3K/Akt phosphorylation. Angiogenesis 2009, 12:313-324.
53. Aymerich M.S., Alberdi E.M., Martínez A., Becerra S.P. Evidence for pigment epithelium-derived factor receptors in the neural retina. Invest Ophthalmol Vis Sci 2001, 42:3287-3293.
54. Alberdi E., Aymerich M.S., Becerra S.P. Binding of pigment epithelium-derived factor (PEDF) to retinoblastoma cells and cerebellar granule neurons. Evidence for a PEDF receptor. J Biol Chem 1999, 274:31605-31612.
55. Ho T.C., Chen S.L., Yang Y.C., Liao C.L., Cheng H.C., Tsao Y.P. PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells. Cardiovasc Res 2007, 76:213-223.
56. Ho T.C., Chen S.L., Yang Y.C., Lo T.H., Hsieh J.W., Cheng H.C., et al. Cytosolic phospholipase A2-{alpha} is an early apoptotic activator in PEDF-induced endothelial cell apoptosis. Am J Physiol, Cell Physiol 2009, 296:C273-C284.